MCID: CRD246
MIFTS: 56

Cardiovascular System Disease

Categories: Blood diseases, Cardiovascular diseases, Immune diseases

Aliases & Classifications for Cardiovascular System Disease

MalaCards integrated aliases for Cardiovascular System Disease:

Name: Cardiovascular System Disease 12 15
Disease of Subdivision of Hemolymphoid System 12
Abnormality of the Cardiovascular System 29
Disorder of Cardiovascular System 29
Cardiovascular Diseases 44
Cardiovascular Disease 17

Classifications:



External Ids:

Disease Ontology 12 DOID:1287
ICD9CM 34 429.2
MeSH 44 D002318
NCIt 50 C2931
SNOMED-CT 67 266275004
ICD10 32 I51.6
UMLS 71 C0007222

Summaries for Cardiovascular System Disease

Disease Ontology : 12 A disease of anatomical entity which occurs in the blood, heart, blood vessels or the lymphatic system that passes nutrients (such as amino acids and electrolytes), gases, hormones, blood cells or lymph to and from cells in the body to help fight diseases and help stabilize body temperature and pH to maintain homeostasis.

MalaCards based summary : Cardiovascular System Disease, also known as disease of subdivision of hemolymphoid system, is related to coronary heart disease 1 and vascular disease. An important gene associated with Cardiovascular System Disease is MIR210 (MicroRNA 210), and among its related pathways/superpathways are Adipogenesis and Folate Metabolism. The drugs Hydroxocobalamin and Gliclazide have been mentioned in the context of this disorder. Affiliated tissues include endothelial, heart and kidney, and related phenotypes are cardiovascular system and liver/biliary system

Wikipedia : 74 Cardiovascular disease (CVD) is a class of diseases that involve the heart or blood vessels. CVD... more...

Related Diseases for Cardiovascular System Disease

Diseases in the Cardiovascular System Disease family:

Autoimmune Disease of Cardiovascular System

Diseases related to Cardiovascular System Disease via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 1367)
# Related Disease Score Top Affiliating Genes
1 coronary heart disease 1 33.1 SERPINE1 INS CRP APOE APOB APOA1
2 vascular disease 33.0 SERPINE1 REN NOS3 MIR145 MIR143 INS
3 heart conduction disease 32.8 SERPINE1 REN INS IL6 CRP APOE
4 pericardium disease 32.7 REN IL6 CRP ALB ACE
5 tangier disease 32.7 APOE APOB APOA1 ALB
6 prediabetes syndrome 32.6 SERPINE1 INS CRP APOB APOA1 ADIPOQ
7 lipid metabolism disorder 32.6 SERPINE1 INS IL6 CRP APOE APOB
8 hyperlipidemia, familial combined, 3 32.5 INS APOE APOB APOA1 ADIPOQ
9 platelet glycoprotein iv deficiency 32.5 INS APOE APOB
10 arteriolosclerosis 32.4 REN APOE ALB ADIPOQ
11 diabetes mellitus 32.4 SERPINE1 REN NOS3 MIR210 MIR145 INS
12 hypertension, essential 32.4 SERPINE1 REN NOS3 MIR210 MIR145 MIR143
13 hypercholesterolemia, familial, 1 32.4 NOS3 INS CRP APOE APOB APOA1
14 type 2 diabetes mellitus 32.4 SERPINE1 REN NOS3 INS IL6 CRP
15 atherosclerosis susceptibility 32.3 SERPINE1 NOS3 INS IL6 CRP CDKN2B-AS1
16 cerebrovascular disease 32.3 SERPINE1 REN INS IL6 CRP APOE
17 body mass index quantitative trait locus 11 32.3 SERPINE1 REN NOS3 MIR143 MIR10A INS
18 peripheral vascular disease 32.3 SERPINE1 IL6 CRP APOB APOA1 ALB
19 sleep apnea 32.2 SERPINE1 REN NOS3 INS IL6 CRP
20 angina pectoris 32.2 NOS3 INS IL6 CRP APOA1 ADIPOQ
21 congestive heart failure 32.1 REN NOS3 INS IL6 CRP CDKN2B-AS1
22 peripheral artery disease 32.1 NOS3 IL6 CRP CDKN2B-AS1 APOE APOB
23 arteriosclerosis 32.1 SERPINE1 NOS3 INS IL6 CRP APOE
24 aortic aneurysm 32.1 MIR145 IL6 HIF1A-AS1 CRP CDKN2B-AS1 APOE
25 heart disease 32.1 SERPINE1 REN NOS3 MIR210 MIR145 MIR143
26 chronic kidney disease 32.0 SERPINE1 REN NOS3 INS IL6 CRP
27 dilated cardiomyopathy 32.0 SERPINE1 REN NOS3 IL6 CRP APOE
28 intermediate coronary syndrome 32.0 MIR145 INS IL6 CRP APOB APOA1
29 pulmonary hypertension 32.0 SERPINE1 REN NOS3 IL6 CRP ALB
30 myocardial infarction 32.0 SERPINE1 REN NOS3 MIR210 INS IL6
31 osteoporosis 32.0 SERPINE1 NOS3 INS IL6 CRP APOE
32 aortic aneurysm, familial abdominal, 1 31.9 SERPINE1 REN NOS3 IL6 CRP CDKN2B-AS1
33 placenta disease 31.9 REN INS IL6 CRP ADIPOQ
34 hepatic lipase deficiency 31.9 APOE APOA1
35 hypertriglyceridemia, familial 31.9 SERPINE1 INS APOE APOB APOA1
36 hyperglycemia 31.9 SERPINE1 NOS3 INS IL6 APOB ALB
37 homocysteinemia 31.9 SERPINE1 NOS3 CRP APOE ALB
38 fatty liver disease 31.9 SERPINE1 INS IL6 APOB ADIPOQ
39 arteries, anomalies of 31.8 SERPINE1 REN NOS3 MIR210 MIR145 MIR143
40 pulmonary disease, chronic obstructive 31.8 INS IL6 CRP ALB ACE
41 pre-eclampsia 31.8 SERPINE1 REN NOS3 MIR210 INS IL6
42 lipoprotein quantitative trait locus 31.8 SERPINE1 REN NOS3 MIR145 MIR143 INS
43 end stage renal disease 31.8 REN NOS3 INS IL6 CRP APOB
44 impotence 31.8 NOS3 INS ALB ACE
45 stroke, ischemic 31.8 SERPINE1 REN NOS3 IL6 CRP CDKN2B-AS1
46 heart valve disease 31.8 REN CRP ALB ACE
47 non-alcoholic fatty liver disease 31.8 SERPINE1 INS IL6 CRP APOE APOB
48 kidney disease 31.7 SERPINE1 REN NOS3 INS IL6 CRP
49 microvascular complications of diabetes 3 31.7 REN MIR217 INS ALB ACE
50 hyperuricemia 31.7 REN INS CRP APOB ALB

Graphical network of the top 20 diseases related to Cardiovascular System Disease:



Diseases related to Cardiovascular System Disease

Symptoms & Phenotypes for Cardiovascular System Disease

MGI Mouse Phenotypes related to Cardiovascular System Disease:

46
# Description MGI Source Accession Score Top Affiliating Genes
1 cardiovascular system MP:0005385 10.03 ACE ADIPOQ ALB APOA1 APOB APOE
2 liver/biliary system MP:0005370 9.85 ACE ADIPOQ ALB APOA1 APOB APOE
3 muscle MP:0005369 9.56 ADIPOQ ALB APOB APOE IL6 INS
4 renal/urinary system MP:0005367 9.28 ACE ADIPOQ ALB APOE IL6 INS

Drugs & Therapeutics for Cardiovascular System Disease

Drugs for Cardiovascular System Disease (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 795)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Hydroxocobalamin Approved Phase 4 13422-51-0 11953898 15589840
2
Gliclazide Approved Phase 4 21187-98-4 3475
3
Chlorothiazide Approved, Vet_approved Phase 4 58-94-6 2720
4
Zinc Approved, Investigational Phase 4 7440-66-6 32051
5
Norethindrone Approved Phase 4 68-22-4 6230
6
Metolazone Approved Phase 4 17560-51-9 4170
7
Dimethyl fumarate Approved, Investigational Phase 4 624-49-7 637568 5271565
8
Selenium Approved, Investigational, Vet_approved Phase 4 7782-49-2
9
Fenofibrate Approved Phase 4 49562-28-9 3339
10
Candesartan cilexetil Approved Phase 4 145040-37-5 2540
11
Pravastatin Approved Phase 4 81093-37-0 54687
12
Ritonavir Approved, Investigational Phase 4 155213-67-5 392622
13
Amprenavir Approved, Investigational Phase 4 161814-49-9 65016
14
Emtricitabine Approved, Investigational Phase 4 143491-57-0 60877
15
Levoleucovorin Approved, Investigational Phase 4 68538-85-2 149436
16
Glimepiride Approved Phase 4 93479-97-1 3476
17
Ticagrelor Approved Phase 4 274693-27-5 9871419
18
Sodium citrate Approved, Investigational Phase 4 68-04-2
19
Vildagliptin Approved, Investigational Phase 4 274901-16-5 6918537
20
Telmisartan Approved, Investigational Phase 4 144701-48-4 65999
21
Ramipril Approved Phase 4 87333-19-5 5362129
22
Enalaprilat Approved Phase 4 76420-72-9 6917719
23
Enalapril Approved, Vet_approved Phase 4 75847-73-3 5362032 40466924
24
Insulin glargine Approved Phase 4 160337-95-1
25
Liraglutide Approved Phase 4 204656-20-2 44147092
26
Insulin detemir Approved Phase 4 169148-63-4 5311023
27
Ibuprofen Approved Phase 4 15687-27-1 3672
28
Atenolol Approved Phase 4 29122-68-7 2249
29
Propranolol Approved, Investigational Phase 4 525-66-6 4946
30
Salicylic acid Approved, Investigational, Vet_approved Phase 4 69-72-7 338
31
Tolvaptan Approved Phase 4 150683-30-0 216237
32
Doxazosin Approved Phase 4 74191-85-8 3157
33
Ethinyl Estradiol Approved Phase 4 57-63-6 5991
34
Drospirenone Approved Phase 4 67392-87-4 68873
35
Dipyridamole Approved Phase 4 58-32-2 3108
36
Paclitaxel Approved, Vet_approved Phase 4 33069-62-4 36314
37
Moxifloxacin Approved, Investigational Phase 4 151096-09-2, 354812-41-2 152946
38
Caffeine Approved Phase 4 58-08-2 2519
39
Clonidine Approved Phase 4 4205-90-7 2803
40
Morphine Approved, Investigational Phase 4 57-27-2 5288826
41
Efavirenz Approved, Investigational Phase 4 154598-52-4 64139
42
Lopinavir Approved Phase 4 192725-17-0 92727
43
Celecoxib Approved, Investigational Phase 4 169590-42-5 2662
44
Naproxen Approved, Vet_approved Phase 4 22204-53-1 1302 156391
45
Carvedilol Approved, Investigational Phase 4 72956-09-3 2585
46
Cinacalcet Approved Phase 4 226256-56-0 156419
47
Norgestimate Approved, Investigational Phase 4 35189-28-7 6540478
48
Didanosine Approved Phase 4 69655-05-6 50599
49
Saquinavir Approved, Investigational Phase 4 127779-20-8 60787
50
Stavudine Approved, Investigational Phase 4 3056-17-5 18283

Interventional clinical trials:

(show top 50) (show all 3694)
# Name Status NCT ID Phase Drugs
1 Effects on Incidence of Cardiovascular Events of the Addition of Pioglitazone as Compared With a Sulphonylurea in Type 2 Diabetic Patients Inadequately Controlled With Metformin. Unknown status NCT00700856 Phase 4 add-on pioglitazone;add-on sulphonylurea
2 Effect of aSpirin Versus CilOstazol for Inhibition of Antiplatelet aggRegaTion in Type 2 DM Patients Unknown status NCT02933788 Phase 4 Cilostazol;Acetylsalicylic acid
3 Multicenter, Randomized Trial Designed to Evaluate the Applicability of the Guidelines of the Italian Society of Diabetology for the Prevention of Cardiovascular Diseases in Type 2 Diabetes Unknown status NCT01240070 Phase 4
4 Early Detection of Atherosclerosis in the Primary Care Setting: a Randomized Trial to Assess the Efficacy of a Novel Strategy in the Primary Prevention of Cardiovascular Diseases. Unknown status NCT00734123 Phase 4 Simvastatin or Atorvastatin;Enalapril;Aspirin or clopidogrel;Rimonabant
5 Levosimendan Versus Dobutamine in Cardiopatic Patients Undergoing Major Non Cardiac Surgery Unknown status NCT02012946 Phase 4 Levosimendan;Dobutamine
6 PPARGC1β And CNTN4 Genotype as a Pharmacogenetic Assay of Thrombosis and Bleeding Risks - a Cross-Over Controlled Trial of Aspirin in Individuals at Increased Cardiovascular Risk. Unknown status NCT02970604 Phase 4 Aspirin
7 Investigation of the Atherogenic Effects of Uric Acid-modified in Endothelial Dysfunction and the the Preventional Mechanism by Anthocyanidines Unknown status NCT02797028 Phase 4 Allopurinol
8 Effects of an Exercise Program in Patients With Hypertensive Chronic Kidney Disease: a Randomized Clinical Trial Unknown status NCT01155128 Phase 4
9 Pharmacokinetics and Pharmacodynamics of Ticagrelor in Patients With Stable Angina, NSTEMI and STEMI Undergoing PCI Unknown status NCT02012140 Phase 4 ticagrelor
10 HOPE-2 Study (Heart Outcomes Prevention Evaluation-2 Study) Unknown status NCT00106886 Phase 4 Folic acid, vitamin B6 and B12 or placebo
11 Does Administration of Vitamin D in African Americans With Hypovitaminosis D and Type 2 DM Improve Inflammatory Markers of Cardiovascular Disease? Unknown status NCT01153243 Phase 4 Ergocalciferol;Placebo pill
12 A Morbi-Mortality and Remodeling Study With Valsartan in Patients With Hypertension and Cardiovascular Disease Unknown status NCT00133328 Phase 4 valsartan
13 Effects of Mycophenolate Mofetil (MMF) on Surrogate Markers for Cardiovascular Disease in HIV-1 Infected Patients Unknown status NCT00247494 Phase 4 mycophenol mofetil (MMF, Cellcept®) 500 mg BID
14 Comparison of Ultra-low-dose Oral Versus Trans-dermal Hormone Therapy on Coagulation Activation and Metabolic Risk Factors for Cardiovascular Disease Unknown status NCT02264743 Phase 4 Femoston Conti;EVOREL® CONTI
15 NSAIDs vs. Coxibs in the Presence of Aspirin: Effects on Platelet Function, Endothelial Function, and Biomarkers of Inflammation in Subjects With Rheumatoid Arthritis and Increased Cardiovascular Risk or Cardiovascular Disease Unknown status NCT03699293 Phase 4 celecoxib 200mg capsule;naproxen sodium 550mg tablet;Aspirin 81mg tablet
16 Normal Oxygenation Maintenance in Intensive Care Unit: Randomized Controlled Trial Unknown status NCT01319643 Phase 4 Oxygen
17 Homocysteine Lowering and Atherosclerosis Reduction Trial (HART) Unknown status NCT00217178 Phase 4 Vitamins: Folic acid, B6, B12
18 Personalized Medicine in HCV Chronic Infection. Endothelial Dysfunction and Subclinical Atheromatosis in Patients With HCV Infection. Characterization and Potential Reversibility With Direct Antiviral Agents. Unknown status NCT02802280 Phase 4
19 Bedside Testing of the CYP2C19 Gene to Asses Effectiveness of Clopidogrel in Coronary Artery Disease Patients Treated With Percutaneous Coronary Intervention : Individualized Antiplatelet Drugs Treatment to Improve Prognosis Unknown status NCT01823185 Phase 4 clopidogrel;Ticagrelor or prasugrel
20 Phase IV: A Comparison of Reduced-dose Prasugrel and Clopidogrel in Elderly Patients With Acute Coronary Syndrome Undergoing Early Percutaneous Coronary Intervention (PCI) Unknown status NCT01777503 Phase 4 prasugrel;Clopidogrel
21 Prospective Comparison of Metolazone Versus Chlorothiazide for Acute Decompensated Heart Failure With Diuretic Resistance Unknown status NCT03574857 Phase 4 Metolazone Oral Tablet;Chlorothiazide Injection
22 Effectiveness and Safety of Low-dose vs. High-dose Rosuvastatin on Long-term Cardiovascular Events in Korean Patients After Percutaneous Coronary Intervention: 30-month, Prospective, Single-center, Randomized Trial Unknown status NCT02859480 Phase 4 Rosuvastatin 5mg;Rosuvastatin 20mg
23 Pulse Wave Velocity, Pulse Wave Morphology and Blocking of the Reninangiotensin System in Patients With Chronic Kidney Disease: An Interventional and Methodological Study Unknown status NCT00235287 Phase 4 Candesartan and enalapril;candesartan and enalapril;candesartan and enalapril;candesartan and enalapril
24 The Influence of Adalimumab vs. Fumaric Acid Esters on Cardiovascular and Metabolic Risk Factors in the Therapy of Patients With Moderate to Severe Psoriasis Vulgaris Unknown status NCT01088165 Phase 4 Adalimumab treatment arm;Fumaric acid esters treatment group
25 Hemocontrol's Effectiveness in a RAndomized Controlled Trial on the Reduction of Cardiovascular Long-term EventS Unknown status NCT01515878 Phase 4
26 Effects of Empagliflozin on Cardiac Structure, Function, and Circulating Biomarkers in Patients With Type 2 Diabetes Unknown status NCT02998970 Phase 4 Empagliflozin;Placebo
27 Adalimumab to Mitigate Cardiovascular Risk in RA Patients With Well-Controlled Joint Disease Unknown status NCT01893996 Phase 4 Adalimumab;Placebo
28 Multi-centre Clinical Trial on Hormone Replacement Treatment in China Unknown status NCT01698164 Phase 4 estradiol plus MPA;Ximingting Tablet;estradiol plus progesterone
29 Effect of Treating Sleep Apnea With Oral Appliances in the Elderly: ORACLE Study Unknown status NCT02325089 Phase 4
30 Randomized Clinical Study to Assess the Safety and the Effects of Isolated Left Ventricular Pacing in Patients With Bradyarrhythmias Unknown status NCT01717469 Phase 4
31 An Open-label, Multi-center Study to Evaluate the Efficacy and Safety of Statin-fenofibrate Combination Therapy in Dyslipidemic Chinese Patients Completed NCT01462877 Phase 4 fenofibrate
32 Hydroxychloroquine for the Prevention of Recurrent Cardiovascular Events in Myocardial Infarction Patients - a Safety Pilot Trial Completed NCT02648464 Phase 4 Hydroxychloroquine;Placebo
33 Comparison of the Efficacy of Everolimus-Eluting Versus Zotarolimus-Eluting Stent for Coronary Lesions in Acute Myocardial Infarction Completed NCT01347554 Phase 4
34 A 12-week Multicenter, Randomized, Double-blind, Parallel-group, Active-control Study to Evaluate the Antihypertensive Efficacy and Safety of Valsartan/Amlodipine-based Regimen Versus a Losartan-based Regimen in Patients With Stage 2 Systolic Hypertension Completed NCT00931710 Phase 4 valsartan, amlodipine, HCTZ;Losartan, HCTZ followed by valsartan, amlodipine, HCTZ
35 Cilostazol Enhances the Number and Functions of Circulating Endothelial Progenitor Cells Mediated Through Multiple Mechanisms in Patients With High Risk for Cardiovascular Disease Completed NCT02194686 Phase 4 Cilostazol;Dummy Placebo
36 Subclinical Cardiovascular Disease in Psoriatic Disease Completed NCT03228017 Phase 4 Aspirin and/or Atorvastatin
37 Evaluation the Effect of the Double Maintenance Dose of Clopidogrel Versus Single Dose in Patients With Coronary Artery Disease With a BMI ≥ 27 kg.m-2 Completed NCT01509365 Phase 4 clopidogrel;clopidogrel
38 Living With Statins - The Impact of Cholesterol Lowering Drugs on Health, Lifestyle and Well-being Completed NCT02255682 Phase 4 Simvastatin
39 Effects of Valsartan on the Progression of Renal and Cardiovascular Disease - Kanagawa Valsartan Trial (KVT) Completed NCT00190580 Phase 4 valsartan;Conventional antihypertensive drugs
40 Post-prandial Lipid Effects of Raltegravir (RAL) vs Ritonavir-boosted Darunavir (DRV-r) in Anti-retroviral Therapy (ART)-Naive Adults or Adults Recommencing ART. Completed NCT01258439 Phase 4 raltegravir plus truvada;Darunavir, ritonavir, tenofovir/emtricitabine (Truvada)
41 Pharmacokinetics of Single-Dose Oral Ranolazine in Hemodialysis Patients Completed NCT01435174 Phase 4 Ranolazine
42 Does Atorvastatin Reduce Ischemia-Reperfusion Injury in Humans in-Vivo? Completed NCT00441597 Phase 4 atorvastatin
43 Effects of Strict Volume Control in Hypertensive Hemodialysis Patients on Cardiac Structure and Chronic Inflammation: a Randomised, Prospective and Controlled Study Completed NCT00307463 Phase 4
44 Study of Heart and Renal Protection (SHARP): The Effects of Lowering LDL-cholesterol With Simvastatin 20mg Plus Ezetimibe 10mg in Patients With Chronic Kidney Disease: a Randomized Placebo-controlled Trial Completed NCT00125593 Phase 4 Simvastatin 20 mg;Ezetimibe 10mg;Placebo
45 The Effect of Ezetimibe 10 mg, Simvastatin 20 mg and the Combination of Simvastatin 20 mg Plus 10 mg Ezetimibe on Low Density Lipoprotein (LDL)-Subfractions in Patients With Type 2 Diabetes Completed NCT01384058 Phase 4 ezetimibe;simvastatin;Ezetimibe 10/Simvastatin 20
46 A 30 Day International, Randomized, Parallel-group, Double-blind, Placebo-controlled Phase IV Study to Evaluate Efficacy and Safety of Pre-hospital vs. In-hospital Initiation of Ticagrelor Therapy in STEMI Patients Planned for PCI. Completed NCT01347580 Phase 4 Ticagrelor;Placebo
47 The Novel Antihypertensive Goal Of hYpertension With diAbetes - Hypertensive Events and ARb Treatment (NAGOYA-HEART) Study Completed NCT00129233 Phase 4 Valsartan;Amlodipine
48 Yoga for the Management of HIV-Metabolic Syndromes Completed NCT00627380 Phase 4
49 A Multi-center, Randomized, Double-blind, Placebo-controlled Clinical Trial to Evaluate the Effect of 52 Weeks Treatment With Vildagliptin on Left Ventricular Function in Patients With Type 2 Diabetes and Congestive Heart Failure Completed NCT00894868 Phase 4 vildagliptin;placebo of vildagliptin
50 A Twelve-week, Randomized, Double-blind, Parallel Group Study to Evaluate the Prolonged Efficacy and Safety of Aliskiren 300 mg Compared to Telmisartan 80 mg in Mild to Moderate Hypertensive Patients With the 24-hour Ambulatory Blood Pressure Measurement After 1 Week of Treatment Withdrawal Study Acronym: ASSERTIVE - AliSkiren Study of Profound antihypERtensive Efficacy in hyperTensIVE Patients Completed NCT00865020 Phase 4 Aliskiren;Telmisartan;Placebo to Aliskiren;Placebo to Telmisartan

Search NIH Clinical Center for Cardiovascular System Disease

Cochrane evidence based reviews: cardiovascular diseases

Genetic Tests for Cardiovascular System Disease

Genetic tests related to Cardiovascular System Disease:

# Genetic test Affiliating Genes
1 Disorder of Cardiovascular System 29 ACE
2 Abnormality of the Cardiovascular System 29

Anatomical Context for Cardiovascular System Disease

MalaCards organs/tissues related to Cardiovascular System Disease:

40
Endothelial, Heart, Kidney, Bone, Liver, Brain, Ovary

Publications for Cardiovascular System Disease

Articles related to Cardiovascular System Disease:

(show top 50) (show all 2962)
# Title Authors PMID Year
1
Intracellular delivery strategies for microRNAs and potential therapies for human cardiovascular diseases. 47
21045204 2010
2
MicroRNA-10a regulation of proinflammatory phenotype in athero-susceptible endothelium in vivo and in vitro. 47
20624982 2010
3
MicroRNA 217 modulates endothelial cell senescence via silent information regulator 1. 47
19786632 2009
4
miR-145 and miR-143 regulate smooth muscle cell fate and plasticity. 47
19578358 2009
5
MicroRNA-210 modulates endothelial cell response to hypoxia and inhibits the receptor tyrosine kinase ligand Ephrin-A3. 47
18417479 2008
6
Identification of risk genes related to myocardial infarction and the construction of early SVM diagnostic model. 61
33352151 2020
7
Effects of SARS-CoV-2 and its functional receptor ACE2 on the cardiovascular system. 61
33025029 2020
8
[Study on mechanism of Tibetan medicine Zuomua Decoction in treatment of hypertension based on network pharmacology and molecular docking technology]. 61
33350197 2020
9
Unraveling the genetic causes in large pedigrees with gout by whole‑exome sequencing. 61
32124961 2020
10
Revisiting Tumors and the Cardiovascular System: Mechanistic Intersections and Divergences in Ferroptosis. 61
32908642 2020
11
Citric acid-enhanced dissolution of polyphenols during soaking of different teas. 61
31506961 2019
12
A novel antioxidant Mito-Tempol inhibits ox-LDL-induced foam cell formation through restoration of autophagy flux. 61
30321700 2018
13
Screening key genes for abdominal aortic aneurysm based on gene expression omnibus dataset. 61
29439675 2018
14
Circular RNA WDR77 target FGF-2 to regulate vascular smooth muscle cells proliferation and migration by sponging miR-124. 61
29042195 2017
15
[Nursing care in elderly patients with cardiovascular disease]. 61
28976398 2017
16
Multi-scale Modeling of the Cardiovascular System: Disease Development, Progression, and Clinical Intervention. 61
27138523 2016
17
Farnesoid-X-receptor expression in monocrotaline-induced pulmonary arterial hypertension and right heart failure. 61
26392308 2015
18
[Hyperprolactinaemia and bone mineral density]. 61
26319389 2015
19
Elderly deaths in Ankara, Turkey. 61
24962235 2014
20
Association of adrenergic receptor gene polymorphisms in gallbladder cancer susceptibility in a North Indian population. 61
24556804 2014
21
Denervation of nerve terminals in renal arteries: one-year follow-up of interventional treatment of arterial hypertension. 61
24408071 2014
22
[Retrospective analysis of 190 cases of hospitalized patients with psoriasis]. 61
24384952 2013
23
[Biomarkers and risk factors of cardiovascular system disease in diabetes mellitus type 2]. 61
23951913 2013
24
Atrial natriuretic peptide and oxidative stress. 54
20385186 2010
25
No or only population-specific effect of PON1 on human longevity: a comprehensive meta-analysis. 54
20362697 2010
26
Adenoviral-mediated overexpression of DDAH improves vascular tone regulation. 54
20219849 2010
27
Neuropeptide Y and sleep. 54
20122859 2010
28
Hyperglycemia and oxidative stress strengthen the association between myeloperoxidase and blood pressure. 54
20385972 2010
29
Regulatory polymorphism in transcription factor KLF5 at the MEF2 element alters the response to angiotensin II and is associated with human hypertension. 54
20086047 2010
30
Dalcetrapib: a review of Phase II data. 54
20465364 2010
31
Soluble form of a receptor for advanced glycation end products (sRAGE) as a biomarker. 54
20515790 2010
32
Residential traffic exposure, pulse pressure, and C-reactive protein: consistency and contrast among exposure characterization methods. 54
20123638 2010
33
ADMA, C-reactive protein, and albuminuria in untreated essential hypertension: a cross-sectional study. 54
20189274 2010
34
Changes in the immune system during menopause and aging. 54
20515802 2010
35
Novel substituted heteroaromatic compounds as inhibitors of stearoyl-CoA desaturase. 54
20205608 2010
36
Association of serum adiponectin with risk for cardiovascular events in patients with peripheral arterial disease. 54
20096841 2010
37
Therapeutic interventions to enhance apolipoprotein A-I-mediated cardioprotection. 54
20297868 2010
38
Albuminuria, impaired kidney function and cardiovascular outcomes or mortality in the elderly. 54
20008829 2010
39
N-terminal ProBNP distribution and correlations with biological characteristics in apparently healthy Greek population: ATTICA study. 54
19815605 2010
40
Vitamin E reduces cardiovascular disease in individuals with diabetes mellitus and the haptoglobin 2-2 genotype. 54
20415560 2010
41
Gene therapy to improve high-density lipoprotein metabolism and function. 54
20196736 2010
42
Aldose reductase and cardiovascular diseases, creating human-like diabetic complications in an experimental model. 54
20466987 2010
43
Exploring the potential of NO-independent stimulators and activators of soluble guanylate cyclase for the medical treatment of erectile dysfunction. 54
20201788 2010
44
[Anti-diabetic drugs for secondary prevention of cardiovascular disease in mild diabetic and IGT patients: ABC study and PPAR study]. 54
20446588 2010
45
High mobility group box-1 and cardiovascular diseases. 54
20464035 2010
46
Pro-atherothrombotic effects of leptin in human coronary endothelial cells. 54
20174754 2010
47
Higher leptin levels in Asian Indians than Creoles and Europids: a potential explanation for increased metabolic risk. 54
20125099 2010
48
Hormonal modulation of endothelial NO production. 54
20213497 2010
49
Leptin-induced vascular smooth muscle cell proliferation via regulating cell cycle, activating ERK1/2 and NF-kappaB. 54
20458445 2010
50
A significant decline in IGF-I may predispose young Africans to subsequent cardiometabolic vulnerability. 54
20215395 2010